Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • News
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • News
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. NATtrol Controls
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

NATtrol Controls

[0900-F70101-N-2] Plain Control Liposomes for Clophosome (Neutral), 2 ml
Plain Control Liposomes for Clophosome (Neutral), 2 ml
260.00 € 260.0 EUR
[0900-F70101-N-10] Plain Control Liposomes for Clophosome (Neutral), 10 ml
Plain Control Liposomes for Clophosome (Neutral), 10 ml
539.00 € 539.0 EUR
[0015-20017-2-1] Pig IgM (swine non-immune, isotype control), purified - 0.5 mG.
Pig IgM (swine non-immune, isotype control), purified - 0.5 mG.
450.00 € 450.0 EUR
[0015-20017-4-1-25] Pig IgA (swine non-immune, isotype control), purified - 25 ug.
Pig IgA (swine non-immune, isotype control), purified - 25 ug.
500.00 € 500.0 EUR
[0015-20017-4-100-100] Pig IgA (swine non-immune, isotype control), purified - 100 ug.
Pig IgA (swine non-immune, isotype control), purified - 100 ug.
943.00 € 943.0 EUR
[0131-PA807] Pancreatic cancer tissue array, with cancer adjaceent tissue and normal tissue as control, including duct adenocarcinoma(PADC), cancer adjaceent pancreatic and normal tissue TNM, clinical stage and pathology grade, 80 cases/ 80 cores(1.5mm)
Pancreatic cancer tissue array, with cancer adjaceent tissue and normal tissue as control, including duct adenocarcinoma(PADC), cancer adjaceent pancreatic and normal tissue TNM, clinical stage and pathology grade, 80 cases/ 80 cores(1.5mm)
415.00 € 415.0 EUR
[0002-MDZ049] Norovirus GI/GII Positive Control 6 X 0.5 mL
Norovirus GI/GII Positive Control 6 X 0.5 mL
561.00 € 561.0 EUR
[0015-NMOS-CD1-5] Normal Mouse control serum, CD-1 (Pre-immune) - 5 mL
Normal Mouse control serum, CD-1 (Pre-immune) - 5 mL
374.00 € 374.0 EUR
[0002-NATNG-6MC-IVD] Neisseria gonorrhoeae Positive Control Pack - 6 X 1.25 mL
Neisseria gonorrhoeae Positive Control Pack - 6 X 1.25 mL
600.00 € 600.0 EUR
[676-TC-9082-NC] Negative Control for TC-9082/EZ-PED/TGE/PDCoV MPX 1.1 Master Mix and Enzyme
Negative Control for TC-9082/EZ-PED/TGE/PDCoV MPX 1.1 Master Mix and Enzyme
225.00 € 225.0 EUR
[0868-G211v1.1] NGS CF Control Panel G211 v1.1 - 6 x 50 µL
NGS CF Control Panel G211 v1.1 - 6 x 50 µL
1,702.00 € 1702.0 EUR
[0002-NATSPY-6MC] NATtrol Strep A Positive Control (6 x 0.5mL)
NATtrol Strep A Positive Control (6 x 0.5mL)
345.50 € 345.5 EUR
[0002-NATSPY-6L] NATtrol Strep A Positive Control (6 x 0.25 mL)
NATtrol Strep A Positive Control (6 x 0.25 mL)
384.60 € 384.6 EUR
[0002-NATSDG-6MC] NATtrol Strep A Negative Control (6 x 0.5mL)
NATtrol Strep A Negative Control (6 x 0.5mL)
533.00 € 533.0 EUR
[0002-NATSARS(COV2)-ERC] NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL)
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL)
749.00 € 749.0 EUR
[0002-NATFRC-6C-IVD] NATtrol SARS-CoV-2 Flu/RSV Positive Control (6 x 0.5mL) CE IVD
NATtrol SARS-CoV-2 Flu/RSV Positive Control (6 x 0.5mL) CE IVD
515.00 € 515.0 EUR
[0002-NATSARS(COV2)-ERC-IVD] NATtrol SARS Associated Coronavirus 2 Positive Control (6 x 0.5 mL)
NATtrol SARS Associated Coronavirus 2 Positive Control (6 x 0.5 mL)
416.75 € 416.75 EUR
[0002-NATSARS(COV2)-NEG] NATtrol SARS Associated Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL)
NATtrol SARS Associated Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL)
399.00 € 399.0 EUR
[0002-NATMSSA-6MC-IVD] NATtrol SA Positive Control (6 x 0.5 mL) CE IVD
NATtrol SA Positive Control (6 x 0.5 mL) CE IVD
588.00 € 588.0 EUR
[0002-NATRPC-NNS] NATtrol Respiratory Pathogen (RP) Control (12 x 0.25 mL)
NATtrol Respiratory Pathogen (RP) Control (12 x 0.25 mL)
803.00 € 803.0 EUR
  • 3
  • 4
  • 5
  • 6
  • 7

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)